HIV Cases Rising Among 50+ Age Group, Says Alarming Lancet Report
Last Updated:
The report warns that HIV spreads via shared needles, unsafe injections and improper transfusions, posing a risk not just to youth but to people of all ages
A recent report published in The Lancet has raised alarms among health experts, highlighting a sharp rise in HIV cases among people aged 50 and above.
While HIV is commonly linked to sexual transmission and often perceived as a disease affecting younger individuals, the report stresses that the virus can spread through multiple routes, including shared needles, unsafe injections, and improper blood transfusions, making it a risk for people of all ages.
The study, published in The Lancet Healthy Longevity journal, reveals that HIV prevalence among older adults now surpasses that of younger individuals. Dr. Louiser Olubayo of the Sydney Brenner Institute for Molecular Bioscience notes that most awareness campaigns focus primarily on youth, leaving the older population overlooked. This age group often assumes they're not at risk, a misconception deeply rooted in societal attitudes.
Preventing HIV among the elderly requires a proactive approach. First, it's vital to recognise that HIV is entirely treatable, and early diagnosis greatly improves outcomes. However, older individuals are less likely to get tested, often resulting in delayed detection and limited access to timely treatment.
Experts recommend annual HIV testing, which is both affordable and widely available, typically costing less than Rs 100.
Raising awareness among the elderly is crucial, and government-led campaigns are needed to promote regular HIV testing in this age group. Encouraging safe sex practices and ensuring hygienic injection methods are also key to prevention. Seniors should seek immediate medical attention if they experience symptoms like excessive sweating, tongue blisters, persistent fever, fatigue, weakness, sudden weight loss, or unexplained skin rashes.
First Published:
May 08, 2025, 17:41 IST
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
44 minutes ago
- Indian Express
No CDSCO certificate, incomplete docs: Health dept orders inquiry over irregularities in medical equipment purchase
Maharashtra's Public Health Department has directed the Maharashtra Medical Goods Procurement Authority (MMGPA) to probe and submit a report on the alleged irregularities in awarding tenders of Rs 56 crore for the purchase of medical equipment. The allegations against the tender process involve that of financial irregularity as well as violating the administrative proceedings to favour select contractors. Earlier this year, the MMGPA had floated a tender to procure essential medical equipment like cell counter, microscope, lab autoclave, haemoglobin meter, haemoglobin strips, lithotomy table and lamp. A total of 5 companies participated in this tender, out of which only 2 were qualified. A complaint has been submitted with the Public Health department which alleges, CDSCO (Central Drug Standards Control Organisation) certificate was not submitted for medical equipment like autoclave and microscope, even though it was mandatory and tenders were awarded despite incomplete documents. It has been alleged that both the qualified bidders are authorised by the same manufacturing company. 'This is a direct violation of the Indian Competition Act 2002 and Tender Rule 2.2.6 (Conflict of Interest). Both the qualified tenderers did not attach the required documents such as work experience, customer testimonials and official tender documents signed by a chartered accountant to prove completion of the work worth Rs 28 crore (mandatory turnover value). The complaint has also mentioned that over all these tender irregularities, one ineligible bidder had duly registered objections with the Health Appeals Department and the Directorate of Industries office. 'However, without properly resolving these objections and doubts, the price envelope was opened in a hurry and the ineligible bidder was qualified and given a work order and a contract. This action clearly shows the complete lack of transparency in the tender process,' the complaint said. The public health department on June 4 asked MMGPA to undertake detailed inquiry into the objections raised against the tender process and submit the report at the earliest.
Time of India
2 hours ago
- Time of India
Kerala HC sets aside state govt order stipulating internship fee for foreign medical graduates
Kochi: High court has set aside the state govt's order stipulating an internship fee for foreign medical graduates (FMGs). The bench of Justice N Nagaresh further observed that, as the National Medical Commission (NMC) Act mandates stipend payment to medical interns for their service, the state is not justified in levying an internship fee from medical graduates. The Court was considering a batch of petitions filed by FMGs challenging the GO dated April 3, 2025, issued by the health department additional secretary, which directed them to pay Rs 5,000 per month as an internship fee for the Compulsory Rotating Medical Internship (CRMI). The petitioners, who secured medical degrees from institutions outside India, contended that the NMC, which has the power under the Act to make policy regarding the internship, provides no option for the state to levy any fee for CRMI and had already directed that no such fee should be charged. The state opposed the arguments and submitted that the NMC cannot restrain state govts from levying an internship fee on Indian or foreign medical graduates. In 2020, the state had fixed the internship fee at Rs 10,000 per month for FMGs, and, in view of directions from a HC division bench in a previous petition, the govt had refixed the fee at Rs 5,000 per month. Meanwhile, the NMC clarified that it had taken a policy decision directing that no internship fee shall be collected from students undergoing CRMI. Accordingly, HC set aside the impugned GO mandating the internship fee for FMGs.
Time of India
2 hours ago
- Time of India
Dr Reddy's, Alvotech to co-develop Keytruda biosimilar
Dr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of Keytruda, a highly successful cancer drug. This partnership aims to provide more affordable treatment options globally as Merck's patents begin to expire around 2028. The collaboration will enhance Dr. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Mumbai: Dr Reddy's Laboratories has entered into a collaboration with Reykjavik, Ireland-based biotech company Alvotech to co-develop, manufacture and commercialise a biosimilar version of blockbuster cancer drug Keytruda for the global (generic name is pembrolizumab ), manufactured and marketed by Merck & Co , is the most successful medicine, recording worldwide sales of $29.5 billion in 2024. It is used to treat multiple forms of the terms of the agreement, both companies will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities, Hyderabad-based DRL said in a statement on to certain exceptions, each party will have the right to commercialise the product traditional generics, which often face automatic patent infringement claims, biosimilars are developed more like original drugs, complete with clinical trials and patent disclosures, giving them a better chance of overcoming legal challenges. Also, Merck's core patents on pembrolizumab in the US are expected to start expiring around 2028.'This (collaboration) demonstrates our ability to develop and manufacture high quality and affordable treatment options for patients worldwide,' Erez Israeli, chief executive of DRL, said.Róbert Wessman, chairman and CEO of Alvotech, said, 'The agreement enables us to increase the availability of cost-effective, critical biologic medications to patients worldwide.'Keytruda is approved in the US to treat 40 cancers, unlike most medicines that treat a few indications or medical India, it is approved for use in 17 indications across 10 cancers or tumour types. Oncologists mostly prescribe it to treat certain types of lung cancers, followed by gastrointestinal cancer, triple-negative breast cancer and head and neck helps the body's immune system, which is the T-cells, to detect and fight cancer cells that hide and spread in organs.'Oncology has been a top focus therapy area for us, and this collaboration will enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in immuno-oncology ,' Israeli has been out of reach for most patients in India due to its exorbitant cost – roughly about Rs 2 lakhs for each dose. However, with Merck's patent set to expire in a few years and with Indian drug manufacturers looking to come up with more affordable versions of the drug it may play a crucial role in widening adoption across a larger cohort of patients.
